Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Capital Expenditures (2016 - 2025)

Medifast (MED) has disclosed Capital Expenditures for 16 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 40.88% year-over-year to $1.4 million, compared with a TTM value of $5.6 million through Dec 2025, down 24.68%, and an annual FY2025 reading of $5.6 million, down 24.68% over the prior year.
  • Capital Expenditures was $1.4 million for Q4 2025 at Medifast, down from $1.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $11.6 million in Q4 2021 and bottomed at $946000.0 in Q4 2023.
  • Average Capital Expenditures over 5 years is $3.5 million, with a median of $1.9 million recorded in 2024.
  • The sharpest move saw Capital Expenditures surged 2529.07% in 2021, then plummeted 89.56% in 2023.
  • Year by year, Capital Expenditures stood at $11.6 million in 2021, then fell by 22.02% to $9.1 million in 2022, then tumbled by 89.56% to $946000.0 in 2023, then skyrocketed by 141.54% to $2.3 million in 2024, then plummeted by 40.88% to $1.4 million in 2025.
  • Business Quant data shows Capital Expenditures for MED at $1.4 million in Q4 2025, $1.4 million in Q3 2025, and $1.4 million in Q2 2025.